Life sciences software company Optive Research has launched its
latest software for in silico drug discovery, making it
faster and easier for chemists to 'invent' new compounds for
lead discovery.
Genes, which are linked to either resistance or sensitivity to four
major cancer drugs used to treat acute lymphoblastic leukaemia
(ALL) has led to the suggestion that these genes determine
treatment outcome and may represent future...
Scientists may be fighting a losing battle to develop alternative
treatments to drug resistant pathogens, as research reveals the
evolution of drug resistance in bacteria is a trait that is
favoured through the process of natural...
The market for oligonucleotides is set to more than double in the
next few years, promising rewards for those companies that can meet
the demand for custom ingredients and manufacturing services.
New treatment strategies for the hepatitis C virus (HCV) based on a
specific combination of genes that directly give protection against
HCV without the necessity for additional treatment for a virus that
affects 170 million people...
Pharmaceutical companies seeking to design more effective
chemotherapy drugs will be encouraged by the latest discovery that
has isolated the independent mechanisms of action of two anticancer
drugs. This revelation provides drug...
Drug discovery company PerkinElmer and biotechnology company
Vivascience has announced the formation of a joint partnership and
distribution agreement in biomarker screening and discovery.
Aurora Discovery has introduced a low volume-handling instrument
that enables highly automated miniaturization of research assays
for life science laboratories specialising in drug research and
development.
A report into the protein biochip industry identifies a major trend
emerging in protein production, either driven by gene approaches or
research purposes for therapeutic drug production. The report cites
growth in the US market to...
Germany'sLion Bioscience has reported a slight financial
improvement from a year ago, trimming losses in the first quarter.
53 per cent of the Lion's Q1 revenues, or €2.1 million were
generated from Bayer projects.
US pharmaceutical giant Bristol-Myers Squibb (BMS) is to pay $150
million (€122 million) to settle an investigation in which
regulators claimed the company gave investors an inaccurate
representation of its financial performance by...
Applied Imaging has announced the release of Ariol 2.0, the latest
generation of its Ariol imaging analysis system, providing a suite
of advanced image analysis technologies for cancer testing and drug
discovery.
Research into obesity treatment and its related disorders took
another step forward after two studies isolated drug targets that
could prove effective for the millions who suffer from
obesity-related problems.
SurfE2ROne, a new detection technology for drug discovery and
development, has been launched by its makers IonGate Biosciences
who believe that in using this technology drugs can be developed
faster and more efficiently.
Emerging nanomedicine technologies could find an increasing place
in various areas and applications of the healthcare sector
including drug discovery and development, drug delivery and
providing targeted therapy, according to a new...
The identification of an oncogene, which is associated with brain
cancers, could lead to the development of targeted molecular
therapeutics, controlling brain cancer development through
regulation of the errant gene.
A new screening technique has been developed to target genes that
change patients' responses to cancer drugs and other medications.
By identifying genetic factors affecting patients drug responses,
customisable treatment plans...
The first grants given in the UK for drug development in early
phase clinical experiments have been awarded to gene therapy trials
that may herald a breakthrough in intra-abdominal cancer which has
an average survival rate of less...
Life sciences company Tepnel has signed a conditional agreement to
acquire OpiSAS' (Opi) subsidiary Diaclone Research, a company that
produces monoclonal antibodies for in vitro studies and
diagnostic purposes.
Despite Thermo Electron reporting a Q2 revenue growth of 12 per
cent, organic revenue growth declined from 5 per cent in 1Q04 to 3
per cent in the second quarter, due in part to the company's sale
of its Optical Technologies...
A potential new drug target for treatment of cancer has amazed
scientists who believe it plays such a key role in preventing
cancer onset that it opens up a range of different targeting
options for multiple types of cancer.
Locus Pharmaceuticals have acquired the drug discovery company
Protein Mechanics, which brings together novel technologies that
broaden the scope of drug targets and further strengthens its
position as a leading company in computational...
A new drug target, which blocks the reproduction of cancerous cells
without the side effects commonly associated with existing cancer
drugs, has been discovered by scientists who believe this target is
linked to other diseases including...
In a defiant gesture to animal activists, Britain's pharmaceutical
companies have joined forces to launch a £4m research fund to
finance animal experiments in universities.
A novel approach to treating tuberculosis (TB), focusing on a
potential drug target in the cell walls of Mycobacterium
tuberculosis, the bacterium that causes TB, a disease that is
reappearing as new, multiresistant drug-strains.
Contract service provider, GeneLogic, has formed a partnership with
Millenium Pharmaceuticals acquiring a technology program and an
associated research team as part of the deal. Millenium becomes the
first customer for this new service...
Scientists who have discovered the binding site for the
anti-epilepsy drug Keppra have confirmed that the drugs mechanism
of action places it in a new class of central nervous system (CNS)
drugs.
The reality of the violence of some UK animal activists became
apparent after GlaxoSmithKline (GSK), Europes's biggest drug maker,
warned that investment and jobs would be driven out of the country
by their actions.
Celera Diagnostics announced it has entered into a collaboration
with Merck to identify novel targets for drug discovery and
diagnostic markers related to Alzheimer's disease.
An antibody drug candidate to treat autoimmune diseases has been
exclusively in-licensed by KaloBios Pharmaceuticals who hope to
develop this compound into a practicable treatment for rheumatoid
arthritis (RA), which currently...
Pharmaceutical instrument supplier Argonaut believes its Isolute
ppt+ protein precipitation plates can overcome two major obstacles
holding back the purity of protein precipitation prior to LC-MS
analysis of drugs and metabolites...
The chief executive of leading pharmaceutical company, Astra
Zeneca, has issued a bleak warning to European governments: improve
the business environment, or we'll take our investment elsewhere.
The battle to gain control of the lucrative cholesterol-lowering
drug market intensified after Merck and Schering-Plough joined
forces to win Food and Drug Administration (FDA) approval for their
new entrant, Vytorin.
Pharmaceutical instrument supplier Argonaut has introduced the
Isolute PPT+ protein precipitation plates, created with the
intention of accelerating drug research and development.
US biotechnology company Invitrogen reported record second-quarter
revenue but warned that top-line growth for the rest of 2004 would
be less than expected, citing an increasingly competitive business
environment.
A novel approach to traditional drug design has led to a new drug
which prevents eye scarring after glaucoma surgery. The discovery
brings hope to half a million people in the UK who suffer from what
is the most common cause of irreversible...
Ciphergen Biosystems has introduced its next generation ProteinChip
System, Series 4000, primarily designed to enable rapid biomarker
discovery and development of predictive, high throughput
SELDI-based assays.
Pharmaceutical investment in antibiotic research and development
(R&D) must be reinvigorated so doctors have access to medicines
needed to combat the ever-growing threat of antibiotic resistant
infections.
Tecan has launched the Freedom EVO 96R and EVO 384R, two new
integrated multi-channel pipetting platforms for liquid handling
applications. These systems will be presented at the "Drug
Discovery Technology" exhibition in...
In the first study of its kind, researchers have identified the
genes in non-cancerous supporting cells that can encourage the
growth of breast cancer cells. The findings suggest aiming
chemotherapy at both normal and cancer cells...
Researchers have developed the first tool to identify and study
individual neurons activated in a living animal, ultimately leading
to the development of targeted drugs that directly affect neurons
involved in neurological diseases...
A step forward has been taken in understanding the genetic disorder
Huntingdon's after the discovery of a protein whose mutation causes
it to stop functioning properly and trigger the disease.
The market for the tools and services in combinatorial chemistry
and high-throughput screening approached $3 billion in 2003
(€2.43bn), but a new set of challenges is shifting customers'
focus, according to a new study.
Clinomics Biosciences has signed a collaboration agreement with the
Moffitt Cancer Centre with a primary objective to jointly develop
new technologies for use in cancer research.
US company QuantomiX has introduced its QX capsule technology to
the European research market allowing researchers for the first
time to directly image cells in their native wet environment with a
standard scanning electron microscope...
Global efforts to develop a vaccine to prevent HIV infection and
AIDS have intensified over the past few years, yet they continue to
fall short of what is likely to be needed to achieve success,
reports Phil Taylor.
A natural mutation of a gene that helps regulate the reactivity of
the immune system is a major contributor to type 1 diabetes,
researchers have found, writes Wai Lang Chu..
Evident Technologies, a company in the market for quantum dots (a
tool for fluorescence detection in biological systems) has started
commercial production of its first biotinylated reagents.
Researchers in the US have provided the first direct evidence in
mice for the role of an enzyme that specifically controls the
production of serotonin in the brain.